Authorized purpose: Provides volumetric hyperdensity segmentation and quantification as an aid; physicians must review original images.
Clinical role
A parallel workflow tool that uses a locked AI/ML algorithm to outline intracranial hyperdense areas on NCCT head scans and quantify their volume; its DICOM output is sent to PACS with the original NCCT series for physician review.
Images and patients
CT/CTA · Brain
Key limitation
Keep in mind: Does not provide lateral-ventricle volume or midline shift and is not a replacement for physician image review.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Provides volumetric hyperdensity segmentation and quantification as an aid; physicians must review original images.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain Input: Adult single-timepoint non-contrast head CT.
Who uses it?Intended users: Medical imaging professionals and trained clinicians.
What does the software produce?Output: DICOM summary and segmentation series with RGB overlays and hyperdensity volume labels; colors are only for visual differentiation between segmented regions and have no meaning on their own.
What is its most important limitation?Key limitation: Does not provide lateral-ventricle volume or midline shift and is not a replacement for physician image review.
Clinical takeaway. Clinical role: Provides volumetric hyperdensity segmentation and quantification as an aid; physicians must review original images.
Evidence takeaway. Evidence from the reviewed source record: Regulatory segmentation agreement testing is submission-specific; clinical diagnostic-performance metrics were not abstracted.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Provides volumetric hyperdensity segmentation and quantification as an aid; physicians must review original images.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
A parallel workflow tool that uses a locked AI/ML algorithm to outline intracranial hyperdense areas on NCCT head scans and quantify their volume; its DICOM output is sent to PACS with the original NCCT series for physician review.
Exact FDA submission
Checked 2026-11-14
Packet wording: "uses a locked artificial intelligence machine learning (AI/ML) algorithm to process non-contrast head CT (NCCT) scans to outline intracranial hyperdense areas and then quantify the volume of intracranial hyperdensities" … "Brainomix 360 Hyperdensity is a parallel workflow tool installed across the neurology network in healthcare facilities to identify and communicate images". Read from the exact FDA decision document on 2026-11-14.
DICOM summary and segmentation series with RGB overlays and hyperdensity volume labels; colors are only for visual differentiation between segmented regions and have no meaning on their own.
Exact FDA submission
Checked 2026-09-19
The exact device description states the DICOM series, RGB overlay, volume-label, and color-meaning boundaries.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Regulatory segmentation agreement testing is submission-specific; clinical diagnostic-performance metrics were not abstracted.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Adult single-timepoint non-contrast head CT.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Automated DICOM routing sends original images and results to preconfigured PACS destinations; the DICOM Network Integration Module uses DICOM C-STORE.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: DICOM summary and segmentation series with RGB overlays and hyperdensity volume labels; colors are only for visual differentiation between segmented regions and have no meaning on their own.
Scope: Exact FDA submission. The exact device description states the DICOM series, RGB overlay, volume-label, and color-meaning boundaries.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: DICOM summary and segmentation series with RGB overlays and hyperdensity volume labels; colors are only for visual differentiation between segmented regions and have no meaning on their own.
Scope: Exact FDA submission. The exact device description states the DICOM series, RGB overlay, volume-label, and color-meaning boundaries.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Brainomix's current official FAQ describes ISO 27001, GDPR, and DPA controls for the current Brainomix 360 family; this does not establish certificate scope, expiry, deployed configuration, or exact K243294 security controls.
Product family
Checked 2026-10-25
Obtain current certificate scope, data-processing terms, hosting region, encryption, identity/access, audit, retention, and incident-response evidence for the deployed release.
The PCCP permits model retraining and threshold adjustment within the cleared indications; models are locked before release and do not continuously learn.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
The exact packet identifies non-contrast CT as the supported imaging modality. Controlled directory display reconciled from exact FDA wording: Non-Contrast CT (NCCT). -> CT/CTA.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-19Last searched
25Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
No stored literature or trial candidates; empty metadata snapshots were screened. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, acr ai central product, vendor documentation, fda decision summary, vendor product page, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-06 - Exact product version
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "Brainomix 360 reimbursement CPT NTAP"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No Brainomix page naming coding or payment for this product was found. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
Authorized purpose: Rapid CTA 360 analyzes adult head CTA DICOM images to flag suspected large- and medium-vessel occlusion in specified intracranial and vertebral segments and notify trained clinicians for workflow triage; notifications are informational and not diagnostic.
Authorized purpose: Viz Subdural+ labels, visualizes, and quantifies subdural collections from single-time-point non-contrast head CT, reporting collection grayscale value, total volume, widest width, and midline shift as annotated DICOM images for physician review with original CT.
Authorized purpose: Brainomix 360 e-ASPECTS registers adult non-contrast brain CT, segments ASPECTS regions, and provides an editable ASPECTS score with highlighted regions and voxel contribution views to assist trained clinicians evaluating suspected ischemic stroke within 24 hours of last known well.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.